Comparative Pharmacology
Head-to-head clinical analysis: CETIRIZINE HYDROCHLORIDE versus KETOTIFEN FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CETIRIZINE HYDROCHLORIDE versus KETOTIFEN FUMARATE.
CETIRIZINE HYDROCHLORIDE vs KETOTIFEN FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1-receptor antagonist; inhibits histamine-mediated allergic and inflammatory responses.
Antihistamine and mast cell stabilizer; inhibits release of histamine and other mediators from mast cells; also blocks histamine H1 receptors.
5-10 mg orally once daily; maximum 10 mg per day.
1 mg orally twice daily; ophthalmic: 1 drop in each eye every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 8-11 hours in healthy adults; prolonged in renal impairment (up to 20-30 hours in moderate to severe impairment).
Terminal half-life 12-24 hours (mean 18 hours); requires twice-daily dosing after initial titration.
Primarily renal (approximately 70% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Renal (50-70% as conjugates, <2% unchanged), fecal (<10%), with enterohepatic circulation.
Category A/B
Category A/B
Antihistamine
Antihistamine / Mast Cell Stabilizer